• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于恶性黑素瘤治疗的新潜在药物-2020-2022 年最新研究。

New Potential Agents for Malignant Melanoma Treatment-Most Recent Studies 2020-2022.

机构信息

Independent Radiopharmacy Unit, Faculty of Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland.

Department of Dermatology, Venerology and Pediatric Dermatology, Medical University of Lublin, 20-081 Lublin, Poland.

出版信息

Int J Mol Sci. 2022 May 29;23(11):6084. doi: 10.3390/ijms23116084.

DOI:10.3390/ijms23116084
PMID:35682764
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9180979/
Abstract

Malignant melanoma (MM) is the most lethal skin cancer. Despite a 4% reduction in mortality over the past few years, an increasing number of new diagnosed cases appear each year. Long-term therapy and the development of resistance to the drugs used drive the search for more and more new agents with anti-melanoma activity. This review focuses on the most recent synthesized anti-melanoma agents from 2020-2022. For selected agents, apart from the analysis of biological activity, the structure-activity relationship (SAR) is also discussed. To the best of our knowledge, the following literature review delivers the latest achievements in the field of new anti-melanoma agents.

摘要

恶性黑素瘤（MM）是最致命的皮肤癌。尽管在过去几年中死亡率降低了 4%，但每年新诊断出的病例数量却在不断增加。长期的治疗和对所用药物的耐药性的发展促使人们不断寻找更多具有抗黑色素瘤活性的新药物。本综述重点介绍了 2020 年至 2022 年合成的最新抗黑色素瘤药物。对于选定的药物，除了分析生物活性外，还讨论了结构-活性关系（SAR）。据我们所知，以下文献综述提供了新的抗黑色素瘤药物领域的最新成果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/291aba5d12f6/ijms-23-06084-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/b0b1d1ec2137/ijms-23-06084-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/68a52b8a70f2/ijms-23-06084-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/5457c58636ce/ijms-23-06084-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/33be5b6bf902/ijms-23-06084-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/d1d2bf168408/ijms-23-06084-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/8062fd7f608a/ijms-23-06084-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/a986acc2c059/ijms-23-06084-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/65f6ce1f6da3/ijms-23-06084-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/7ba25aa35bf4/ijms-23-06084-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/5c3bf702c5e8/ijms-23-06084-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/c47a346c01b8/ijms-23-06084-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/84de9d311886/ijms-23-06084-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/291aba5d12f6/ijms-23-06084-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/b0b1d1ec2137/ijms-23-06084-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/68a52b8a70f2/ijms-23-06084-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/5457c58636ce/ijms-23-06084-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/33be5b6bf902/ijms-23-06084-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/d1d2bf168408/ijms-23-06084-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/8062fd7f608a/ijms-23-06084-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/a986acc2c059/ijms-23-06084-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/65f6ce1f6da3/ijms-23-06084-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/7ba25aa35bf4/ijms-23-06084-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/5c3bf702c5e8/ijms-23-06084-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/c47a346c01b8/ijms-23-06084-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/84de9d311886/ijms-23-06084-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3810/9180979/291aba5d12f6/ijms-23-06084-g013.jpg

相似文献

1
New Potential Agents for Malignant Melanoma Treatment-Most Recent Studies 2020-2022.用于恶性黑素瘤治疗的新潜在药物-2020-2022 年最新研究。
Int J Mol Sci. 2022 May 29;23(11):6084. doi: 10.3390/ijms23116084.
2
Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.BRAF 突变型黑色素瘤的耐药性：最新作用机制及有前途的靶向药物综述。
Eur J Pharmacol. 2019 Nov 5;862:172621. doi: 10.1016/j.ejphar.2019.172621. Epub 2019 Aug 22.
3
Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.选择性泛 RAF 抑制剂 TAK-632 在 BRAF 抑制剂耐药性黑色素瘤中的抗肿瘤活性。
Cancer Res. 2013 Dec 1;73(23):7043-55. doi: 10.1158/0008-5472.CAN-13-1825. Epub 2013 Oct 11.
4
Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.新型 MAPK 通路抑制剂在 BRAF 突变型黑色素瘤领域的研究进展。
Clin Cancer Res. 2019 Oct 1;25(19):5735-5742. doi: 10.1158/1078-0432.CCR-18-0836. Epub 2019 Apr 16.
5
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.黑色素瘤分子靶向治疗耐药的克服机制与策略
Cancer. 2017 Jun 1;123(S11):2118-2129. doi: 10.1002/cncr.30435.
6
Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.维莫非尼治疗转移性黑色素瘤的皮肤表现。
J Drugs Dermatol. 2015 May;14(5):509-10.
7
Adaptive resistance to RAF inhibitors in melanoma.黑色素瘤中 RAF 抑制剂的适应性耐药。
Pigment Cell Melanoma Res. 2014 Nov;27(6):1032-8. doi: 10.1111/pcmr.12264. Epub 2014 Jun 6.
8
Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?BRAF抑制剂在黑色素瘤治疗中的长期影响：是友是敌？
Expert Opin Pharmacother. 2014 Apr;15(5):589-92. doi: 10.1517/14656566.2014.881471. Epub 2014 Jan 24.
9
Novel inhibitors in the treatment of metastatic melanoma.用于治疗转移性黑色素瘤的新型抑制剂。
Expert Rev Anticancer Ther. 2007 May;7(5):715-24. doi: 10.1586/14737140.7.5.715.
10
Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma.最近获得专利的抗癌药物的安全性概况和药物警戒学考虑因素：皮肤黑色素瘤。
Recent Pat Anticancer Drug Discov. 2019;14(3):203-225. doi: 10.2174/1574892814666190726130351.

引用本文的文献

1
Primary adrenal melanoma with extensive metastasis: a case report and literature review.原发性肾上腺黑色素瘤伴广泛转移：一例报告及文献复习
Front Oncol. 2025 Aug 14;15:1654218. doi: 10.3389/fonc.2025.1654218. eCollection 2025.
2
Ursolic acid interaction with transcription factors BRAF, V600E, and V600K: a computational approach towards new potential melanoma treatments.熊果酸与转录因子 BRAF、V600E 和 V600K 的相互作用：一种针对新的潜在黑色素瘤治疗方法的计算方法。
J Mol Model. 2024 Oct 10;30(11):373. doi: 10.1007/s00894-024-06165-y.
3
Current advance of nanotechnology in diagnosis and treatment for malignant tumors.

本文引用的文献

1
Target-based anticancer indole derivatives and insight into structure‒activity relationship: A mechanistic review update (2018-2021).基于靶点的抗癌吲哚衍生物及其构效关系洞察：机制综述更新（2018 - 2021年）
Acta Pharm Sin B. 2022 Jul;12(7):3006-3027. doi: 10.1016/j.apsb.2022.03.021. Epub 2022 Apr 1.
2
How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistance.干性标志物醛脱氢酶1家族成员A1（ALDH1A1）如何与肿瘤血管生成、进展及耐药性相关联。
Cancer Drug Resist. 2020 Mar 19;3(1):26-37. doi: 10.20517/cdr.2019.70. eCollection 2020.
3
Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.
纳米技术在恶性肿瘤诊断与治疗中的最新进展。
Signal Transduct Target Ther. 2024 Aug 12;9(1):200. doi: 10.1038/s41392-024-01889-y.
4
Causal relationship between atrial fibrillation/warfarin and cutaneous melanoma: a two-sample Mendelian randomization study.心房颤动/华法林与皮肤黑色素瘤之间的因果关系：一项两样本孟德尔随机化研究。
Front Med (Lausanne). 2024 Mar 5;11:1336849. doi: 10.3389/fmed.2024.1336849. eCollection 2024.
5
Melanoma biology and treatment: a review of novel regulated cell death-based approaches.黑色素瘤生物学与治疗：基于新型程序性细胞死亡方法的综述
Cancer Cell Int. 2024 Feb 9;24(1):63. doi: 10.1186/s12935-024-03220-9.
6
Revisiting the Role of B-RAF Kinase as a Therapeutic Target in Melanoma.重新审视 B-RAF 激酶在黑色素瘤治疗中的作用。
Curr Med Chem. 2024;31(15):2003-2020. doi: 10.2174/0109298673258495231011065225.
7
Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective.BRAF 突变型皮肤黑色素瘤中的自噬：最新进展与治疗前景
Cell Death Discov. 2023 Jun 29;9(1):202. doi: 10.1038/s41420-023-01496-w.
8
Cytotoxic, Antibacterial, and Antioxidant Activities of the Leaf Extract of ..的叶提取物的细胞毒性、抗菌和抗氧化活性
Plants (Basel). 2023 Feb 14;12(4):859. doi: 10.3390/plants12040859.
9
The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma.吲哚胺 2,3-双加氧酶 1（IDO1）的信号功能促使小鼠 B16 黑色素瘤的恶性进展。
Oncoimmunology. 2023 Jan 26;12(1):2170095. doi: 10.1080/2162402X.2023.2170095. eCollection 2023.
10
Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold-A Short Review of Most Recent Studies 2013-2022.端酚氧基作为药物支架的优势部分——对 2013 年至 2022 年最新研究的综述。
Int J Mol Sci. 2022 Aug 9;23(16):8874. doi: 10.3390/ijms23168874.
伊布替尼治疗实体瘤：现有知识状况和未来方向。
Cells. 2022 Apr 14;11(8):1338. doi: 10.3390/cells11081338.
4
The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma.皮肤恶性黑色素瘤的治疗现状与未来方向
Biomedicines. 2022 Mar 31;10(4):822. doi: 10.3390/biomedicines10040822.
5
Design, Synthesis and Biological Activity Testing of Library of Sphk1 Inhibitors.设计、合成及 Sphk1 抑制剂文库的生物活性测试。
Molecules. 2022 Mar 21;27(6):2020. doi: 10.3390/molecules27062020.
6
Antimicrobial and Cytotoxic Activity of Novel Imidazolium-Based Ionic Liquids.新型咪唑基离子液体的抗菌和细胞毒性活性。
Molecules. 2022 Mar 18;27(6):1974. doi: 10.3390/molecules27061974.
7
Potential Anticancer Agents against Melanoma Cells Based on an As-Synthesized Thiosemicarbazide Derivative.基于合成的硫代卡巴肼衍生物的潜在抗癌剂对黑素瘤细胞的作用。
Biomolecules. 2022 Jan 18;12(2):151. doi: 10.3390/biom12020151.
8
Synthesis of cinnamic acid ester derivatives with antiproliferative and antimetastatic activities on murine melanoma cells.合成具有抗增殖和抗转移活性的肉桂酸酯衍生物对鼠黑色素瘤细胞。
Biomed Pharmacother. 2022 Apr;148:112689. doi: 10.1016/j.biopha.2022.112689. Epub 2022 Feb 8.
9
Cinnamic acid derivatives linked to arylpiperazines as novel potent inhibitors of tyrosinase activity and melanin synthesis.肉桂酸衍生物与芳基哌嗪相连，作为新型酪氨酸酶活性和黑色素合成的有效抑制剂。
Eur J Med Chem. 2022 Mar 5;231:114147. doi: 10.1016/j.ejmech.2022.114147. Epub 2022 Jan 29.
10
Optimization and SAR investigation of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as EGFR and BRAF dual inhibitors with potent antiproliferative and antioxidant activities.新型2,3-二氢吡嗪并[1,2-a]吲哚-1,4-二酮衍生物作为具有强效抗增殖和抗氧化活性的EGFR和BRAF双重抑制剂的优化及构效关系研究
Bioorg Chem. 2022 Mar;120:105616. doi: 10.1016/j.bioorg.2022.105616. Epub 2022 Jan 19.